|Home | About | Journals | Submit | Contact Us | Français|
Prolonged human immunodeficiency virus-1 (HIV-1) infection leads to neurological debilitation, including motor dysfunction and frank dementia. Although pharmacological control of HIV infection is now possible, HIV-associated neurocognitive disorders (HAND) remain intractable. Here, we report that chronic treatment with erythropoietin (EPO) and insulin-like growth factor-I (IGF-I) protects against HIV/gp120-mediated neuronal damage in culture and in vivo.
Initially, we tested the neuroprotective effects of various concentrations of EPO, IGF-I, or EPO+IGF-I from gp120-induced damage in vitro. To assess the chronic effects of EPO+IGF-I administration in vivo, we treated HIV/gp120-transgenic or wild-type mice transnasally once a week for 4 months and subsequently conducted immunohistochemical analyses.
Low concentrations of EPO+IGF-I provided neuroprotection from gp120 in vitro in a synergistic fashion. In vivo, EPO+IGF-I treatment prevented gp120-mediated neuronal loss, but did not alter microgliosis or astrocytosis. Strikingly, in the brains of both humans with HAND and gp120-transgenic mice, we found evidence for hyperphosphorylated tau protein (paired helical filament-I tau), which has been associated with neuronal damage and loss. In the mouse brain following transnasal treatment with EPO+IGF-I, in addition to neuroprotection we observed increased phosphorylation/activation of Akt (protein kinase B) and increased phosphorylation/inhibition of glycogen synthase kinase (GSK)-3β, dramatically decreasing downstream hyperphosphorylation of tau. These results indicate that the peptides affected their cognate signaling pathways within the brain parenchyma.
Our findings suggest that chronic combination therapy with EPO+IGF-I provides neuroprotection in a mouse model of HAND, in part, through cooperative activation of phosphatidylinositol 3-kinase/Akt/GSK-3β signaling. This combination peptide therapy should therefore be tested in humans with HAND.
Human immunodeficiency virus-1 (HIV-1) infection can lead to progressive motor and cognitive dysfunction.1-3 Although survival and morbidity from acquired immunodeficiency syndrome (AIDS) have improved through the use of highly active antiretroviral therapy (HAART), the prevalence of HIV-associated neurologic complications is increasing.2 The increasing prevalence of HIV-associated neurocognitive disorders (HAND) indicates that HAART does not provide sufficient protection against neurological complications and suggests a need for neuroprotective therapies to ameliorate this condition. Although there are several rodent models of HAND, including HIV-1–infected macrophages in subacute combined immunodeficiency mice,4,5 HIV/gp120 envelope protein-expressing transgenic mice have been shown to develop several neuropathologic features associated with HAND, such as dendritic damage, synaptic degeneration, and frank neuronal loss in numerous reports.6,7 It has proven worthwhile to follow these features in gp120-transgenic mice, because they can be predictive of effects in subsequent human clinical trials.8
Concerning potential neuroprotective treatments, erythropoietin (EPO), which is classically known as a kidney-generated hematopoietic growth factor, is also expressed in the central nervous system.9 Insulin-like growth factor-I (IGF-I), which affects differentiation and survival in a variety of cells and tissues, is also expressed in the brain.10,11 Acting via the EPO receptor (EPO-R) and IGF-I receptor, EPO and IGF-I are neuroprotective in a variety of in vitro and in vivo animal models, including damage from excitotoxins, ischemia, and gp120/HIV envelope protein.12-14 Previously, we demonstrated that Janus tyrosine kinase-2 (Jak2) is phosphorylated/activated after EPO binds to the EPO-R, initiating a neuroprotective signaling pathway (Fig 1).15 Phosphorylated Jak2 activates a nuclear factor kappa B (NF-κB) signaling cascade that counteracts caspase activity by upregulating both XIAP and Bcl-2 family members.15,16 Additionally, activation of the EPO and IGF-I receptors leads to activation of multiple biochemical cascades, including the PI3K/Akt signaling pathway, which phosphorylates glycogen synthase kinase (GSK)-3β and several other targets critical to cell survival (see Fig 1).17 Phosphorylation inactivates GSK-3β and thus decreases tau phosphorylation, which in the hyperphosphorylated state is causally associated with neuronal cell injury and death.18,19
Recently, we demonstrated that relatively low concentrations of EPO+IGF-I exert a synergistic effect on activation of the PI3K/Akt pathway in rat cerebrocortical cultures, resulting in neuroprotection from excitotoxic insults and thus potentially avoiding side effects that occur with administration of high doses of either EPO or IGF-I alone.20 Considering this potent neuroprotective action of EPO+IGF-I in culture, the present study was undertaken to investigate if application of these cytokines could not only ameliorate the harmful effects of HIV/gp120 in vitro but also repair neuronal dendritic damage that is known to occur in the gp120-transgenic murine model of HAND in vivo. Here, we show that EPO+IGF-I exerts such effects, at least in part, by decreasing tau hyperphosphorylation via PI3K/Akt-mediated inhibition of GSK-3β activity.
Mixed neuronal/glial cerebrocortical cells were derived from embryonic (E17) Sprague-Dawley rats and plated at a density of 4.5 × 105 per 35 mm dish containing poly-l-lysine–coated glass coverslips in Dulbecco modified Eagle medium with Ham F12 and heat-inactivated iron-supplemented calf serum (Hyclone, Logan, UT) plus 2mM glutamine, 24mM HEPES, and penicillin-streptomycin. The culture medium was changed every other day. After 17 to 21 days in culture, the cells were exposed to HIV/gp120 (200pM) for 24 hours in the presence or absence of various concentrations of EPO, IGF-I, or a combination of EPO+IGF-I. Neuronal viability and apoptosis were analyzed in these cultures as previously described.21 In brief, apoptosis was scored in a blinded fashion as the percentage of NeuN-positive neurons that stained for TUNEL and exhibited a condensed nuclear morphology under epifluorescence microscopy. For the experiments with inhibitors to PI3K, cortical neurons were preincubated in the presence or absence of 50μM of LY294002 for 1 hour prior to EPO+IGF-1 treatment, then exposed to gp120 for 24 hours. Afterwards, cells were homogenized in RIPA buffer and subject to Western blot.
Transgenic mice expressing HIV/gp120 under the control of a modified murine glial fibrillary acidic protein (GFAP) promoter were obtained from Dr Lennart Mucke (Gladstone Institute, University of California, San Francisco, San Francisco, CA). Characteristics of these mice have been previously presented.7,8
HIV−/age-matched controls (35–45 years old) were obtained from the University of California, San Diego Medical Center Autopsy Service. HIV+ cases were from the California NeuroAIDS Tissue Network cohort. The brain regions examined included frontal cortex (gray and white matter), hippocampus, caudate, and basal ganglia (putamen and globus pallidus). All HIV+ patients died of respiratory failure due to bronchopneumonia, and the general autopsy findings were consistent with AIDS. The associated pathology was most frequently due to systemic cytomegalovirus, Kaposi sarcoma, and liver disease. Five-micron sections were mounted on glass slides for immunohistochemistry. After deparaffinization in Histoclear, rehydration through graded alcohol solutions, and blockade of endogenous peroxidases in 3% H2O2 for 30 minutes, tissue sections were processed for antigen retrieval using the pressure cooker method. This consisted of a 20-minute incubation at the high setting in Coplin jars filled with Dako Target Retrieval Solution (Dako-Cytomation, Carpinteria, CA). After cooling for 20 minutes, the tissue sections were incubated for an additional 30 minutes in normal goat serum to decrease nonspecific staining. Primary monoclonal antibodies were incubated for 2 hours at room temperature (RT). Following a 30-minute incubation in secondary antibody (biotinylated goat-antimouse) and 30 minutes in Avidin: Biotinylated enzyme Complex (ABC), color reactions were developed with NovaRed (Vector Labs, Burlingame, CA). Sections were counterstained with Meyer hematoxylin.
Mice were anesthetized with isoflurane and maintained under anesthesia for the duration of the treatment. Mice were placed in a supine position, and EPO and/or IGF-I were administered into the nares by pipette in a dropwise fashion in 2μl aliquots, alternating between each nostril every 2 minutes, over a total of 12 minutes. As drug was administered to one naris, the other side was plugged with soft putty. After an initial dose-ranging set of experiments to find the maximally effective concentration of this combination of cytokines, 12μl of a mixture of EPO (50U; Ortho Biotech Products, Raritan, NJ) and IGF-I (2,000ng; Invitrogen, Carlsbad, CA) was administered transnasally.23,24 Prior studies using I125-radiolabeled cytokines had shown that these approximate doses of EPO and IGF-I passed the blood-brain barrier (BBB) and acted synergistically in vivo in the brain during acute neuroprotective experiments.25
For determination of phospho(p)Akt and pGSK-3β activity, olfactory bulb or forebrain was homogenized in ice-cold lysis buffer (Cell Lysis Buffer, Cell Signaling Technology, Beverly, MA) containing protease inhibitor cocktail (Roche Applied Science, Indianapolis, IN). Tissue lysates were centrifuged (15 minutes at 14,000g, 4°C), and supernatants were collected. Protein concentration was determined using a BCA Protein Assay (Pierce Biotechnology, Rockford, IL). Proteins were separated on 4 to 12% NU-PAGE gels (Invitrogen) and transferred onto polyvinylidene difluoride membrane (Immobilon-P, Millipore, Billerica, MA). After blocking with 5% nonfat milk in Tris-buffered saline containing 0.05% Tween 20, the membranes were incubated with primary antibodies overnight at 4°C followed by horseradish peroxidase-conjugated secondary antibody for 1 hour at RT. Protein bands were visualized with enhanced chemoluminescent detection reagents (ECL, Amersham Biosciences, Fairfield, CT; GE Healthcare, Pittsburgh, PA) and exposed to X-ray film (Hyperfilm ECL, Amersham Bioscience). Autoradiographic films were scanned, and densitometric analysis was performed. The following primary antibodies were used: rabbit polyclonal antibody against Akt, pAkt (Ser 473), GSK-3β, pGSK-3β (Cell Signaling Technology), mouse monoclonal antiactin antibody (clone AC-40, Sigma, St. Louis, MO), and phospho-tau (PHF-1) (pSer404) antibody (Sigma). Horseradish peroxidase-conjugated goat antirabbit or antimouse immunoglobulin G (Pierce Biotechnology) was used as a secondary antibody.
For each immunostain, 3 serial sections of corresponding mouse brain regions were analyzed. For assessment of neuronal changes, sections were immunolabeled with antibodies against microtubule-associated protein-2 (MAP-2) (Chemicon, Temecula, CA) to label neuronal cell bodies and dendrites, NeuN (Chemicon) to label neuronal nuclei and cell bodies, GFAP (Chemicon) to label astrocytes in this context, Iba1 (Wako Chemicals, Richmond, VA) to label microglia, and paired helical filament-1 (PHF-1, a gift from P. Davies) to label hyperphosphorylated tau in abnormal filaments. Primary antibody staining was identified with fluorescently tagged secondary antibodies or immunoperoxidase. Sections were examined using a Bio-Rad MRC-1000 laser scanning confocal microscope. Digitized images of 3 optical sections (40μm in thickness) were transferred to a Macintosh computer, running a public domain program (Wayne Rasband), and analyzed as previously described.25 For each case, the frontal cortex (layers 2, 3, and 5) and the hippocampus (molecular layer of dentate gyrus and pyramidal layer of CA1 region) were analyzed quantitatively for each antibody label.
Whole brains from littermate, sex matched, wild-type (WT), and gp120 transgenic 6-week-old mice were homogenized in 2.4ml ice-cold lysis buffer (Cell Lysis Buffer, Cell Signaling Technology) containing protease inhibitor cocktail (Roche Applied Science). Tissue lysates were sonicated and centrifuged for 10 minutes at 14,000g, 4°C, and supernatants were collected and stored at −80°C until used. Protein concentration was determined using a BCA Protein Assay (Pierce Biotechnology) with bovine serum albumin as standard. Quantitative determination of EPO was performed using Quantikine mouse EPO Immunoassay (R&D Systems, Minneapolis, MN). Immunoreactive IGF-I levels were analyzed by a mouse-specific sandwich enzyme-linked immunosorbent assay, developed with a commercially available kit (DuoSet ELISA Development System, R&D Systems). Optical densities were read at 450nm (correction wavelength set at 540nm) by using an automated plate reader, and cytokine levels were calculated by interpolation from the standard curve. Values were corrected for protein concentration. Data were reported as mean ± standard error of the mean and statistically evaluated for difference by Student t test.
We found that 200pM HIV/gp120 increased neuronal apoptosis in mixed neuronal/glial cerebrocortical cultures by ~200% over control (Fig 2). High concentrations of EPO (100U/ml) nearly completely prevented gp120-induced apoptosis, whereas lower concentrations of EPO (10U/ml) produced a substantially smaller reduction in gp120 neurotoxicity, in agreement with prior studies.20 IGF-I (100ng/ml) also offered modest neuroprotection from gp120. Interestingly, our previous studies had demonstrated that low concentrations of EPO+IGF-I act synergistically in cerebrocortical cultures to exert neuroprotection from excitotoxic (N-methyl-d-aspartate [NMDA]) insults.20 Additionally, we had shown that HIV/gp120-induced damage is mediated at least in part via excessive NMDA receptor activation.2,27 Therefore, in the present study, we investigated whether the combination of low concentrations of EPO+IGF-I could protect cultured cerebrocortical neurons from exposure to gp120. We found that the combination of 10U/ml EPO plus 100ng/ml IGF-I completely abrogated gp120-induced neuronal apoptosis, an effect that was more than additive. Thus, the effect of low-dose EPO+IGF-I was at least as protective from gp120-induced toxicity as high-dose EPO alone. Importantly, when administered individually, high doses of EPO or IGF-I exert potentially harmful side effects,28,29 so the attainment of neuroprotection at low doses is of potential clinical utility.
We had previously demonstrated that the PI3K/Akt signaling pathway mediates the synergistic effect of EPO+IGF-I and that inhibiting phosphorylation of Akt, either by dominant negative molecular interference or by pharmacological antagonism, abrogated the neuroprotective effect of these cytokines in cultured cerebrocortical neurons.20 Here, to further dissect the mechanism whereby EPO+IGF-I prevents HIV/gp120-induced neuronal cell death in these cultures, we examined the phosphorylation state of GSK-3β after exposure to gp120 in the presence and absence of EPO+IGF-I. We found that EPO+IGF-I increased both Akt phosphorylation and GSK-3β phosphorylation (Fig 3A), consistent with the notion that EPO+IGF-I exerts its neuroprotective effect at least in part by phosphorylating and thus inactivating GSK-3β, thereby inhibiting tau hyperphosphorylation. Furthermore, inhibiting Akt activation using the PI3K inhibitor LY294002 completely prevented EPO+IGFI-I–induced Akt phosphorylation and GSK-3β phosphorylation compared to control (see Fig 3A), confirming the involvement of the PI3K/Akt/GSK-3β pathway.
Next, we examined the phosphorylation state of tau in these cultures. Tau hyperphosphorylation increased in response to gp120, whereas EPO and/or IGF-I decreased tau hyperphosphorylation, as revealed by immunoblotting (see Fig 3B). Prior work has suggested that hyperphosphorylated tau may contribute to neuronal injury in a number of neurodegenerative disorders, including HAND,30,31 so our finding that EPO+IGF-I completely abrogated PHF-1 formation suggests a possible mechanism for the observed neuroprotection.
To extend our findings on tau hyperphosphorylation to humans, brain samples from patients with HAND were analyzed by Western blot and immunostaining with PHF-1 antibody (Fig 4). The non-HAND cases did not manifest significant neurological impairment. The HAND cases were characterized by the presence of HIV p24 by Western blot and immunohistochemistry, astrogliosis, microglial nodules, and multinucleated giant cells on neuropathological examination, coupled with significant deficits on neuropsychological testing.8 Similar to findings of hyperphosphorylated tau in Alzheimer brains, we found increased staining in the neuropil of the hippocampus and to a lesser extent in the frontal cortex in HAND. Unlike Alzheimer disease, however, frank tangles of hyperphosphorylated tau proteins were not present in the HAND brains.
To begin to apply our findings with EPO+IGF-I in vivo, we measured endogenous IGF-I levels in the gp120-transgenic mouse brain and found that they were significantly lower compared to WT littermates (Supplementary Fig). In the same experimental groups, EPO was not detectable in either WT or gp120-transgenic mouse brain. These findings added further impetus for treating gp120-transgenic mice with EPO+IGF-I.
Next, we investigated if transnasal application of the cytokines could exert an effect across the BBB. Initially, we studied if the Akt/GSK-3β pathway was activated in the olfactory bulb and forebrain following transnasal administration of these peptides. It is well known that transnasal delivery of peptides can facilitate their transport across the BBB, for example, via receptor-mediated endocytosis of endothelial cells,23,32-34 and these cells are known to possess receptors for EPO and IGF-I.32 Transnasal delivery of EPO+IGF-I can limit systemic administration25 and thus the myriad of consequent side effects seen with high-dose parenteral administration of EPO and IGF-I in prior clinical trials.35-38 Based on our in vitro work, we made estimates of the dosage of the cyto-kines that had to be administered in vivo, and then bracketed these amounts for further studies. We thus delivered EPO (50 or 100U) and IGF-I (1,000 or 2,000ng) by transnasal application to 6-month-old HIV/gp120-transgenic or WT mice, and 30 minutes later dissected out the olfactory bulbs/forebrains and performed Western blots. Immunoblotting revealed that Akt was phosphorylated following EPO and/or IGF-I administration (Fig 5A). In particular, the combination of 50U EPO plus 2,000ng IGF-I dramatically increased Akt phosphorylation. Next, we examined whether phosphorylation of GSK-3β was affected in response to transnasal delivery of EPO+IGF-I. As expected, GSK-3β phosphorylation increased after a single administration of EPO+IGF-I and remained elevated in the forebrain for over 24 hours (see Fig 5B, C). These data demonstrate that transnasal application of EPO+IGF-I can activate signaling pathways in the brain that could be potentially neuroprotective in vivo.
Importantly, transnasal administration of EPO did not increase the hematocrit (Hct) after chronic treatment (Hct of vehicle-treated animals, 36%; Hct of EPO+IGF–treated animals, 32%). This result is consistent with the notion that very little systemic absorption occurred with this route of delivery, as we have also recently documented with I125-radiolabeld cytokines; this study also demonstrated that the vast majority of transnasally administered EPO+IGF-I entered the brain.25 Taken together, these findings suggest that fewer systemic side effects will occur following transnasal administration than with standard parenteral administration, and that these cytokines can bypass the BBB and enter the brain from the nasal mucosa.
To study the neuroprotective effect of EPO+IGF-I in an animal model of HAND, we treated gp120-transgenic mice at a time point when damage would have otherwise progressed to cause severe dendritic and neuronal loss.7,8 Starting at 6 months of age, we administered 50U of EPO plus 2,000ng of IGF-I for a period of 4 months to both WT and gp120-transgenic mice. We then analyzed the effects of this treatment on brain sections under laser scanning confocal microscopy. The extent of neuronal damage in the brains of these 10-month-old gp120-transgenic mice was examined by immunostaining for NeuN, MAP-2, GFAP, Iba1, and PHF-1(Fig 6). Significant dendritic damage and frank neuronal loss were detected throughout the cortex and hippocampus of the gp120-transgenic mice when compared with WT mice of the same age, as shown by MAP-2 and NeuN staining. The neuronal damage in the cortex and hippocampus was largely reversed by chronic EPO+IGF-I treatment (see Fig 6D, H and 7A–D). Quantitative analysis of confocal fluorescent images revealed statistically significant increases in the percentage area of neuropil after EPO+IGF-I treatment compared with vehicle-treated gp120 mice, indicating significant protection of the dendritic field. Brain sections of gp120-transgenic mice revealed an increase in neocortical and hippocampal astrogliosis (GFAP staining) and microgliosis (Iba1 staining) compared to WT mice (see Figs 6K, O and 7E–H). The degree of astrocytosis and microglial reactivity was similar in EPO+IGF-I–treated and vehicle-treated gp120 mice (see Figs 6L, P and Fig 7E-H). In line with our evidence for hyperphosphorylation of cortical neurons in vitro after gp120 exposure and with our PHF-1 staining in human brain sections with HAND, both cortical and hippocampal brain sections of gp120-transgenic mice showed statistically significant increases in PHF-1 tau compared to WT mice (p < 0.0001). These data suggest that HIV/gp120 induces hyperphosphorylated tau in a pathophysiologically relevant manner. Moreover, treatment with EPO+IGF-I greatly reduced PHF-1 tau (p < 0.003 and p < 0.01 in cortex and hippocampus, respectively) compared to vehicle-treated gp120-transgenic mice. Taken together, these findings demonstrate that chronic treatment with transnasal EPO+IGF-I produced significant improvements in dendritic complexity and prevention of neuronal degeneration compared to untreated gp120-transgenic mice. On the other hand, EPO+IGF-I manifested no significant effect on astrocytosis or microglial responses.
In the present study, we demonstrate that the HIV envelope glycoprotein gp120 induces neuronal damage and tau hyperphosphorylation in vitro and in vivo. We show that chronic EPO+IGF-I treatment in vitro or in vivo in HIV/gp120-transgenic mice ameliorates this neuronal damage by histological criteria and decreases tau hyperphosphorylation. Prominent HAND neuropathologic features include astrogliosis, activation of microglia, decreased synaptic and dendritic density, and neuronal apoptosis.2,42 Previously, several groups, including our own, had shown that EPO or IGF-I could exert a neuroprotective effect against various forms of neuronal insults.13-15,43 However, the high doses of EPO or IGF-I used in these studies are known to cause systemic side effects. Recently, we found a synergistic effect of EPO+IGF-I at much lower doses,20 so in the present study we took advantage of this synergistic effect for chronic treatment with these cytokines. Additionally, we found that the endogenous IGF-I levels in the gp120-transgenic mouse brain were significantly lower compared to WT littermates, and EPO was not detectable in either WT or gp120 mouse brain. Therefore, together with our finding that EPO+IGF-I synergistically activated the PI3K/Akt neuroprotective pathway, these findings provided a strong rationale for treating gp120-transgenic mice with EPO+IGF-I.
Additional recent studies have shown that acute transnasal treatment of IGF-I and/or EPO can offer protection from experimental brain injury in rat stroke models.25,44,45 It has been suggested that transnasal administration of IGF-I can cross the BBB by an extracellular route along the olfactory bulb or trigeminal neural pathways, as observed by tracing studies with [125I]-IGF-I. Additional reports have suggested that IGF-I and EPO can cross the BBB by endocytosis after binding to IGF-I or EPO receptors that are expressed on the endothelium of brain capillaries.32,34 Thus, transnasal delivery of EPO+IGF-I to the brain may occur via endocytosis as a result of binding of these cytokines to their cognate receptors, or possibly via an extracellular route.
We found several lines of evidence for neuroprotection by the chronic administration of EPO+IGF-I in gp120-transgenic mice, and to our knowledge this represents the first report of successful, low-dose treatment with these cytokines for a prolonged period. From our quantitative confocal microscopy assessments, dendritic area and neuronal survival were improved by this treatment. We have previously demonstrated that 1 mechanism whereby EPO+IGF-I elicits neuroprotection involves activation of the antiapoptotic PI3K/Akt signaling pathway. As shown here, treatment with EPO+IGF-I results in phosphorylation/activation of Akt. Activated Akt then phosphorylates GSK-3β, thus inactivating it and, in turn, preventing phosphorylation of tau protein.
Additionally, we demonstrate here for the first time that hyperphosphorylated tau is more abundant in the brains of human AIDS patients with HAND than in controls, as well as in the brains of HIV/gp120-transgenic mice. It has been surmised by several groups that hyperphosphorylated tau is involved in the pathogenesis of HAND,30,31,46 and several lines of evidence suggest that hyperphosphorylated tau may contribute to neurodegeneration.39,47 Tau can be phosphorylated by various kinases, including protein kinase A, protein kinase C, Jun kinase, p38 mitogen-activated protein kinase, cyclin-dependent kinase 5, and GSK-3β.48-50 Although the mechanism whereby HIV-1 causes tau hyperphosphorylation in HAND brains has yet to be fully elucidated, based on our data we suggest that HIV envelope protein gp120 activates GSK-3β by dephosphorylation, leading to tau hyperphosphorylation, which in turn may potentially contribute to the pathology of HAND. Additionally, in the present study, we found that brains from gp120-transgenic mice expressed abundant levels of PHF-1 tau staining, representing Ser-396/404 PHF-1 sites, which are known to be phosphorylated by GSK-3β. Importantly, we observed a significant decrease in this staining after chronic transnasal treatment with EPO+IGF-I. Taken together, our results suggest that EPO+IGF-I improved the pathological state of gp120 mouse brains, and this neuroprotective effect may possibly have been mediated in part by dephosphorylation of tau, although additional mechanisms of protective action are also possible.
In summary, in the present study we show that chronic transnasal application of EPO+IGF-I induces neuroprotection from gp120 both in vitro and in vivo. We also show that the transnasal route effectively delivers EPO+IGF-I to the brain, and this method can avoid systemic side effects such as a rise in Hct (with consequent thrombosis) or induction of severe cachexia. Moreover, we provide evidence that HAND is associated with hyperphosphorylated tau in the human brain, and that HIV/gp120 can induce hyperphosphorylation of tau. Because reduction in tau phosphorylation after treatment with EPO+IGF-I was accompanied by neuroprotection in the gp120-transgenic mice, we speculate that PHF-1 may serve as a biomarker for the disease process in HAND. Because both EPO and IGF-I are approved for clinical use by the US Food and Drug Administration for other indications, we suggest based on these results that transnasal delivery of EPO+IGF-I should be considered for expedited human therapeutic trials for HAND.
This work was supported in part by NIH grants R01 NS047973, R01 NS046994, R01 NS43242, and R01 EY09024 to S.A.L, MH076681 and MH072529 to C.L.A., and R01 NS050621 to M.K. Additional support was provided by the NIH Blueprint Grant for La Jolla Interdisciplinary Neuroscience Center Cores P30 NS057096 to S.A.L.
We thank T. Fang for preparation of the cerebrocortical cultures, A. Adame and R. Dowen for technical help, K. Walsh for providing adenoviral constructs, and L. Mucke for HIV/gp120-transgenic mice.
Potential Conflicts of Interest
Dr Lipton has served as a consultant to Ortho Biotech, Inc. (J&J, Inc.). Drs Lipton and Digicaylioglu are the named inventors on patent applications filed by their institution for the use of erythropoietin plus insulin like growth factor-I as a disease-modifying treatment for neurodegenerative disorders, including HIV-related conditions.
Additional supporting information can be found in the online version of this article.